Princeton, New Jersey, December 22, 2014 – Sandoz today announced the US market introduction of estradiol transdermal system, an authorized generic version of Vivelle-Dot®, which is marketed by Novartis Pharmaceuticals Corporation.

Estradiol transdermal system is indicated for treatment of certain menopausal symptoms and for the prevention of postmenopausal osteoporosis.

“We are pleased to partner with our colleagues at NPC to further expand our offering of affordable, high-quality medicines,” said Peter Goldschmidt, President of Sandoz Inc.

According to …